French Polynesia vs Norway: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
French Polynesia
0.0%
in 2024
Norway
0.0%
in 2024
French Polynesia rank
143rd
Norway rank
143rd
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- French Polynesia
- Norway
How they compare
French Polynesia currently reports 0.0% against 0.0% in Norway, a difference of 0.0%.
Across all 10 years both countries report, Norway has been ahead every year.
French Polynesia ranks 143rd and Norway ranks 143rd of 215 countries.
Norway has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | French Polynesia | Norway | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.0% | 0.1% | 0.1% | Norway |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, French Polynesia or Norway?
- French Polynesia, at 0.0% against 0.0% in Norway as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between French Polynesia and Norway?
- 0.0%, with French Polynesia ahead.
- How many years of comparable data are there for French Polynesia and Norway?
- 10 years are reported by both, from 2015 to 2024.
- How do French Polynesia and Norway rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- French Polynesia ranks 143rd and Norway ranks 143rd of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.